Ormeloxifene–Looking beyond contraception

Tapasi Pati, Kabita Chanania, Satyabhama Marandi, Jagadish Hansa
In: Journal of Mid-life Health · 2017 · vol. 8(1) , pp. 17 · doi:10.4103/jmh.jmh_71_16 · PMID:28458475 · PMC5367218 · W2600675143
article OA: gold CC0 ⤵ 2 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher

Abstract

AIMS: This study is aimed at finding out a logical solution for perimenopausal menorrhagia in normal or bulky uterus. SETTINGS AND DESIGN: The study is carried out at a tertiary care hospital at Odisha. In our setup, nearly 900 hysterectomies are done per year out of which 60% are for menorrhagia with bulky uterus. SUBJECTS AND METHODS: There were sixty cases of menorrhagia between the ages of 40 and 55 years who completed child bearing treated with ormeloxifene. Their endometrial thickness (ET) and hemoglobin (Hb) level were determined at the start of the study and also at 6 months and compared. At 1 year from the start of treatment, patients' satisfaction and status of menstrual cycle were reassessed. STATISTICAL ANALYSIS USED: < 0.05. RESULTS: < 0.0001). CONCLUSIONS: Ormeloxifene is a safe drug which can be used to treatment of perimenopausal bleeding with minimal focal pathology.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (2)

References (16)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-05-11T05:54:30.111693+00:00
License: CC0 · commercial use OK